Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles : vimarsana.com

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Related Keywords

, Breast Cancer , Clinical Guidelines , Oral Serd , Mbc , Metastatic Breast Cancer , Serd , Therapeutic Advances , Panel Discussion , Er Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Oncologist , Breast Oncology , Elacestrant , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Oral Therapy , Disease Progression , Patient Profiles , Precision Medicine , Metastatic Cancer , Treatment Sequencing , Liquid Biopsy Tissue Testing , Precision Oncology , Therapeutic Strategies , Treatment Failure Criteria , Patient Selection , Dosage Modifications , Toxicity Comparison , Breast Cancer Treatment ,